EASTHAM KARIN — SEC insider filings
SEC reporting owner CIK 1231845. 41 insider filings on record with FilingPulse; latest filed 2026-10-28.
Transaction summary — filings shown
Covers all 41 filings on record, filed 2020-09-24 to 2026-10-28. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 35 legs across 20 filings — 182,188 shares, $151,112,989 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 52.
- Largest priced transaction: sale of 2,959 shares @ $49,015.00 ($145,035,385) in VERACYTE, INC., filed 2021-11-03.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| VERACYTE, INC. (VCYT) | Director | 25 | — | 34 legs · 160,921 sh · $151,036,215 | 28 |
| NEKTAR THERAPEUTICS (NKTR) | Director | 5 | — | 1 leg · 21,267 sh · $76,774 | 8 |
| Personalis, Inc. (PSNL) | Director | 7 | — | — | 10 |
| GERON CORP (GERN) | Director | 4 | — | — | 6 |
Insider filings — EASTHAM KARIN
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-10-28 | 4 | VERACYTE, INC. (VCYT) | Option exercise (M): 10,000 @ $27.01 · Sale (S): 14,850 @ $50.00 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | VERACYTE, INC. (VCYT) | Sale (S): 3,200 @ $52.78 · Sale (S): 529 @ $53.55 | EDGAR |
| 2026-06-15 | 4 | VERACYTE, INC. (VCYT) | Grant/award (A): 5,272 @ $0 | EDGAR |
| 2026-06-11 | 4/A | Personalis, Inc. (PSNL) | Grant/award (A): 6,250 @ $0 | EDGAR |
| 2026-05-14 | 4 | Personalis, Inc. (PSNL) | Grant/award (A): 6,250 @ $0 · Grant/award (A): 37,500 (derivative) @ $0 | EDGAR |
| 2025-12-08 | 4 | VERACYTE, INC. (VCYT) | Option exercise (M): 10,000 @ $7.94 · Option exercise (M): 10,000 @ $7.60 · Sale (S): 6,392 @ $44.52 · Sale (S): 12,808 @ $45.84 · Sale (S): 800 @ $46.59 · Option exercise (M): 10,000 (derivative) @ $0 · +1 more | EDGAR |
| 2025-11-07 | 4 | VERACYTE, INC. (VCYT) | Sale (S): 9,674 @ $40.02 | EDGAR |
| 2025-06-23 | 4 | VERACYTE, INC. (VCYT) | Grant/award (A): 9,321 @ $0 | EDGAR |
| 2025-06-17 | 4 | VERACYTE, INC. (VCYT) | Sale (S): 4,590 @ $26.66 | EDGAR |
| 2025-05-20 | 4 | Personalis, Inc. (PSNL) | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2025-01-06 | 4 | VERACYTE, INC. (VCYT) | Option exercise (M): 10,000 @ $5.28 · Sale (S): 5,309 @ $40.12 · Sale (S): 4,691 @ $40.50 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
| 2024-11-21 | 4 | VERACYTE, INC. (VCYT) | Sale (S): 1,600 @ $36.77 · Sale (S): 3,006 @ $37.77 · Sale (S): 10,125 @ $38.76 | EDGAR |
| 2024-07-18 | 4 | VERACYTE, INC. (VCYT) | Sale (S): 7,500 @ $25 | EDGAR |
| 2024-06-17 | 4 | VERACYTE, INC. (VCYT) | Grant/award (A): 11,473 @ $0 | EDGAR |
| 2024-06-13 | 4 | VERACYTE, INC. (VCYT) | Sale (S): 3,870 @ $20.59 | EDGAR |
| 2024-06-11 | 4 | VERACYTE, INC. (VCYT) | Option exercise (M): 2,500 @ $10.41 · Sale (S): 2,500 @ $20.97 · Option exercise (M): 2,500 (derivative) @ $0 | EDGAR |
| 2024-05-21 | 4 | Personalis, Inc. (PSNL) | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2024-04-02 | 4 | VERACYTE, INC. (VCYT) | Option exercise (M): 10,000 @ $13.19 · Sale (S): 10,000 @ $21.65 · Option exercise (M): 10,000 (derivative) @ $13.19 | EDGAR |
| 2023-06-13 | 4 | VERACYTE, INC. (VCYT) | Grant/award (A): 9,674 @ $0 | EDGAR |
| 2023-05-19 | 4 | Personalis, Inc. (PSNL) | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2023-03-17 | 4 | VERACYTE, INC. (VCYT) | Option exercise (M): 18,750 @ $12.12 · Sale (S): 18,750 @ $22.78 · Option exercise (M): 18,750 (derivative) @ $0 | EDGAR |
| 2023-03-02 | 4 | VERACYTE, INC. (VCYT) | Option exercise (M): 10,000 @ $12.12 · Sale (S): 10,000 @ $25.00 · Option exercise (M): 10,000 (derivative) @ $0 | EDGAR |
| 2023-01-17 | 4 | GERON CORP (GERN) | Option exercise (M): 35,000 @ $1.10 · Option exercise (M): 35,000 (derivative) @ $0 | EDGAR |
| 2022-09-20 | 4 | NEKTAR THERAPEUTICS (NKTR) | Grant/award (A): 10,200 @ $0 · Grant/award (A): 20,400 (derivative) @ $0 | EDGAR |
| 2022-09-14 | 4 | NEKTAR THERAPEUTICS (NKTR) | Sale (S): 21,267 @ $3.61 | EDGAR |
| 2022-06-16 | 4 | VERACYTE, INC. (VCYT) | Grant/award (A): 14,731 @ $0 | EDGAR |
| 2022-05-19 | 4 | Personalis, Inc. (PSNL) | Grant/award (A): 10,770 @ $0 · Grant/award (A): 15,035 (derivative) @ $0 | EDGAR |
| 2022-05-11 | 4 | GERON CORP (GERN) | Grant/award (A): 125,000 (derivative) @ $0 | EDGAR |
| 2022-04-21 | 4 | GERON CORP (GERN) | Option exercise (M): 35,000 @ $1.41 · Option exercise (M): 35,000 (derivative) @ $0 | EDGAR |
| 2021-12-20 | 4 | VERACYTE, INC. (VCYT) | Option exercise (M): 5,000 @ $12.12 · Sale (S): 5,000 @ $45 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2021-11-03 | 4 | VERACYTE, INC. (VCYT) | Sale (S): 200 @ $47.73 · Sale (S): 2,959 @ $49,015 · Sale (S): 1,241 @ $49.48 | EDGAR |
| 2021-09-24 | 4 | NEKTAR THERAPEUTICS (NKTR) | Grant/award (A): 10,200 @ $0 · Grant/award (A): 20,400 (derivative) @ $0 | EDGAR |
| 2021-08-04 | 4 | VERACYTE, INC. (VCYT) | Sale (S): 2,846 @ $43.54 · Sale (S): 1,554 @ $44.57 | EDGAR |
| 2021-06-10 | 4 | VERACYTE, INC. (VCYT) | Grant/award (A): 8,720 @ $0 | EDGAR |
| 2021-05-18 | 4 | Personalis, Inc. (PSNL) | Grant/award (A): 2,736 @ $0 · Grant/award (A): 4,229 (derivative) @ $0 | EDGAR |
| 2021-05-13 | 4 | GERON CORP (GERN) | Grant/award (A): 83,000 (derivative) @ $0 | EDGAR |
| 2021-05-05 | 4/A | VERACYTE, INC. (VCYT) | Option exercise (M): 6,250 @ $4 · Sale (S): 2,444 @ $60.03 · Sale (S): 3,606 @ $61.09 · Sale (S): 200 @ $61.77 · Option exercise (M): 6,250 (derivative) @ $0 | EDGAR |
| 2021-05-05 | 4 | VERACYTE, INC. (VCYT) | Sale (S): 3,527 @ $48.01 · Sale (S): 650 @ $49.00 · Sale (S): 250 @ $50.03 | EDGAR |
| 2021-02-26 | 4 | VERACYTE, INC. (VCYT) | Option exercise (M): 6,250 @ $4 · Sale (S): 2,444 @ $60.03 · Sale (S): 3,606 @ $61.09 · Sale (S): 200 @ $61.77 · Option exercise (M): 6,250 (derivative) @ $0 | EDGAR |
| 2020-09-25 | 4/A | NEKTAR THERAPEUTICS (NKTR) | Grant/award (A): 9,100 @ $0 · Grant/award (A): 18,200 (derivative) @ $0 | EDGAR |
| 2020-09-24 | 4 | NEKTAR THERAPEUTICS (NKTR) | Grant/award (A): 9,100 @ $0 · Grant/award (A): 18,200 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-09-24 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1231845 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs